Celgene (CELG) Offering Possible 47.06% Return Over the Next 27 Calendar Days

Celgene's most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $109.00 short call and a strike $114.00 long call offers a potential 47.06% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $109.00 by expiration. The full premium credit of $1.60 would be kept by the premium seller. The risk of $3.40 would be incurred if the stock rose above the $114.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Celgene is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.

The RSI indicator is at 70.83 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Celgene

Barron's After-Hours: SMART Global Surges, SS&C Technologies Jumps, Celgene Falls
Fri, 22 Dec 2017 01:55:00 +0000
U.S stocks gained on Thursday buoyed by the proposed tax cuts but closed just below their all-time highs. The S&P 500 rose 0.2%, the Dow Jones Industrial Average gained 0.2%, while the Nasdaq Composite …

Celgene's follicular lymphoma regimen fails clinical trial
Thu, 21 Dec 2017 22:52:30 +0000
Celgene Corp said on Thursday it failed to show that combining its cancer drug Revlimid with the cancer drug rituximab was more effective in treating follicular lymphoma than the standard combination of rituximab and chemotherapy. The clinical trial was the first to study a chemotherapy-free regimen in patients with previously untreated follicular lymphoma, a slow-growing form of non-Hodgkin lymphoma. Chemotherapy typically has harsher side effects than more targeted biologic treatments such as Revlimid and rituximab, which is sold by Roche Holding AG under the brand name Rituxan.

6 Stocks Moving In Thursday's After-Hours Session
Thu, 21 Dec 2017 22:27:23 +0000
Gainers: Smart Global Holdings Inc (NASDAQ: SGH ) shares are up 8 percent after reporting a big first-quarter earnings beat. First-quarter adjusted EPS came in at $1.05, topping estimates by 13 cents. …

Celgene's regimen fails to beat chemotherapy in immune system cancer trial
Thu, 21 Dec 2017 22:18:43 +0000
Celgene Corp said its cancer drug in a combination therapy did not prove to be better than another treatment that included standard of care and chemotherapy in newly diagnosed immune system cancer patients in a late-stage study. The study, which tested the company's blockbuster drug, Revlimid, along with rituximab, failed to show that the chemotherapy-free regimen prevented the disease from progressing, compared to the control arm. The late-stage trial also did not show an increase in the number of patients who fully responded to the company's combination treatment, Celgene said.

Stock Update (NASDAQ:CELG): Here’s Why Celgene Corporation Phase III RELEVANCE Trial Outcome Underwhelms the Street
Thu, 21 Dec 2017 22:15:00 +0000
Celgene Corporation (NASDAQ:CELG) and the Lymphoma Study Association (LYSA) gave investors reason to raise a red flag today, as shares start to slip almost 5% in after-hours trading. The Lymphoma Academic Research Organisation (LYSARC) unleashed Phase III RELEVANCE trial results from the drug maker's randomized, open-label, international study evaluating Celgene's Revlimid in combination with Rituximab (R²), designed to treat previously untreated patients suffering from follicular lymphoma.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.